Open Access. Powered by Scholars. Published by Universities.®
Other Pharmacy and Pharmaceutical Sciences Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- ACS (1)
- Colorectal cancer (1)
- Department of Pharmacology and Experimental Therapeutics (1)
- GUCY2C (1)
- Geriatric (1)
-
- Guanylyl cyclase C (1)
- Lymph nodes (1)
- Medication errors (1)
- Medications (1)
- Metastatic disease (1)
- Oncology (1)
- Pharmacists (1)
- Polypharmacy (1)
- Predictive markers (1)
- Prognostic markers (1)
- Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) (1)
- Senior Adult Oncology Center (1)
- Staging (1)
- Thomas Jefferson University (1)
- Publication
- Publication Type
Articles 1 - 2 of 2
Full-Text Articles in Other Pharmacy and Pharmaceutical Sciences
Pharmacists On The Front Lines Of Polypharmacy: The Individualized Medication Assessment And Planning (Imap) Project To Improve Medication Use In Senior Adults With Cancer, Ginah Nightingale Pharmd, Bcop, Laura T. Pizzi Pharmd, Mph, Emily Hajjar Pharmd, Bcps, Bcacp, Cgp, Elizabeth Pigott, Margaret Wang, Shannon Doherty, Kristine Swartz Md, Andrew Chapman Do, Facp
Pharmacists On The Front Lines Of Polypharmacy: The Individualized Medication Assessment And Planning (Imap) Project To Improve Medication Use In Senior Adults With Cancer, Ginah Nightingale Pharmd, Bcop, Laura T. Pizzi Pharmd, Mph, Emily Hajjar Pharmd, Bcps, Bcacp, Cgp, Elizabeth Pigott, Margaret Wang, Shannon Doherty, Kristine Swartz Md, Andrew Chapman Do, Facp
Population Health Matters (Formerly Health Policy Newsletter)
No abstract provided.
Molecular Staging Individualizing Cancer Management, Alex Mejia, Stephanie Schulz, Terry Hyslop, David S. Weinberg, Scott A. Waldman
Molecular Staging Individualizing Cancer Management, Alex Mejia, Stephanie Schulz, Terry Hyslop, David S. Weinberg, Scott A. Waldman
Department of Pharmacology and Experimental Therapeutics Faculty Papers
Although the most important prognostic and predictive marker in colorectal cancer is tumor cells in lymph nodes, ∼30% of patients who are node-negative die from occult metastases. Molecular staging employing specific markers and sensitive detection technologies has emerged as a powerful platform to assess prognosis in node-negative colon cancer. Integrating molecular staging into algorithms that individualize patient management will require validation and the definition of relationships between occult tumor cells, prognosis, and responses to chemotherapy. J. Surg. Oncol. 2012; 105:468-474. © 2012 Wiley Periodicals, Inc.
Copyright © 2012 Wiley Periodicals, Inc.